Gene test could predict kidney cancer in transplant patients
NCT ID NCT03114826
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study examined whether a specific variation in the VEGF gene (rs699947) is linked to a higher risk of developing kidney cancer in people who have received a kidney transplant. Researchers analyzed DNA from 272 transplant patients, some of whom had kidney cancer. The goal was to see if this genetic marker could help identify high-risk patients and guide safer immunosuppressant choices.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors choose safer immunosuppressants for kidney transplant patients at higher genetic risk of kidney cancer.
- What could go wrong
- This is an observational study, not a treatment trial. It only looks for a link between a gene variant and cancer risk, so it cannot prove cause or change care directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYMORPHISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Amiens Picardie
Amiens, Picardie, 80054, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which nerve block offers better pain relief for kidney donors?
- Can a new drug combo help kidney transplants last longer?
- New antibody aims to unlock immune attack on Hard-to-Treat cancers
- Experimental immunotherapy targets tough urinary cancers
- Blood test strategy may spare kidney patients from unnecessary biopsies
- Pilates promises new hope for kidney transplant recovery